Señales en vivo de 4523.T | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 may 2024 @ 20:50):

Stats
Volumen de hoy	257 800
Volumen promedio	1.44M
Capitalización de mercado	1 870.90B
EPS	¥0 ( 2024-02-05 )
Próxima fecha de ganancias	( ¥41.14 ) 2024-05-13
Last Dividend	¥80.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	41.13
ATR14	¥6.19 (0.09%)

Volumen Correlación

Largo: 0.03 (neutral)

Corto: 0.27 (neutral)

Signal:(46.634) Neutral

Eisai Co., Ltd. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eisai Co., Ltd. Correlación - Moneda/Commodity

0.40
( neutral )

-0.17
( neutral )

0.12
( neutral )

0.72
( moderate )

0.00
( neutral )

Eisai Co., Ltd. Finanzas

Annual	2022
Ingresos:	¥744.40B
Beneficio Bruto:	¥566.57B (76.11 %)
EPS:	¥193.31

FY	2022
Ingresos:	¥744.40B
Beneficio Bruto:	¥566.57B (76.11 %)
EPS:	¥193.31

FY	2022
Ingresos:	¥756.23B
Beneficio Bruto:	¥581.40B (76.88 %)
EPS:	¥669.08

FY	2021
Ingresos:	¥645.94B
Beneficio Bruto:	¥484.63B (75.03 %)
EPS:	¥146.95

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥80.00 (N/A)	¥0 (N/A)	¥80.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.47 - Stable (9.32%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥11.50	2000-03-28
Last Dividend	¥80.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥2 807.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.8	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.47
Div. Directional Score	7.74	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.80

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
7971.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7199.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6455.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5451.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4442.T	Ex Dividend Junior	2024-03-28	Insufficient data to determine frequency	0.00%
3636.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2882.T	Ex Dividend Junior	2024-02-28	Semi-Annually	0.00%
1663.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
9757.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
8818.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0606	1.500	8.79	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0346	1.200	8.85	10.00	[0 - 0.3]
returnOnEquityTTM	0.0546	1.500	-0.504	-0.756	[0.1 - 1]
payoutRatioTTM	1.011	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	2.38	0.800	3.10	2.48	[1 - 3]
quickRatioTTM	1.697	0.800	4.72	3.78	[0.8 - 2.5]
cashRatioTTM	1.025	1.500	5.42	8.12	[0.2 - 2]
debtRatioTTM	0.127	-1.500	7.89	-10.00	[0 - 0.6]
interestCoverageTTM	27.29	1.000	1.003	1.003	[3 - 30]
operatingCashFlowPerShareTTM	215.91	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	124.48	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.203	-1.500	9.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.789	1.000	0.176	0.176	[0.2 - 0.8]
operatingProfitMarginTTM	0.0851	1.000	-0.299	-0.299	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.04	9.04	[0.2 - 2]
assetTurnoverTTM	0.572	0.800	9.52	7.62	[0.5 - 2]
Total Score				10.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	41.56	1.000	5.90	0	[1 - 100]
returnOnEquityTTM	0.0546	2.50	-0.324	-0.756	[0.1 - 1.5]
freeCashFlowPerShareTTM	124.48	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.43	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	215.91	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.011	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	2.67	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0826	1.000	-0.434	0	[0.1 - 0.5]
Total Score				5.47

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.